This is in sharp contrast to what is known for intrahepatic cholangiocarcinomas, that have FGFR2 fusions in 10–16% of cases that may be sensitive to infigratinib and pemigatinib5,18–20. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.